RxDoctor Payments Data

Ever Ponciano, MD

Internal Medicine · Hagerstown, MDNPI 1750572012

Payments from drug & device makers

$822in general payments, 2019–2025

Across 50 payments — averaging $16.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$369
  • Novo Nordisk$102
  • AbbVie$77
  • Pfizer$52
  • Abbott$39
  • GSK$35
  • plus $147 from 8 others

What the payments were for

  • Food & beverage$822100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$822 in reported general payments places this provider in the 70th percentile of 2,979 internal medicine providers in Maryland.

See all internal medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$334,539
Medicare patients
690
Services billed
5,598

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide63$108,311
EliquisApixaban71$86,967
TrulicityDulaglutide40$73,703
OzempicSemaglutide39$71,219
JardianceEmpagliflozin30$48,337
Trelegy ElliptaFluticasone/Umeclidin/Vilanter36$41,295
JanuviaSitagliptin Phosphate27$30,960
LinzessLinaclotide23$28,693
ShingrixVaricella-Zoster Ge/As01b/Pf120$27,007
ArexvyRsvpref3 Antigen/As01e/Pf79$24,686
CreonLipase/Protease/Amylase12$24,662
RexultiBrexpiprazole12$18,338
XareltoRivaroxaban15$14,366
Breo ElliptaFluticasone/Vilanterol24$13,395
Duloxetine Hcl162$11,701

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$369$182,014103 claims
GSKTrelegy Ellipta, Shingrix, Arexvy, Breo Ellipta$35$106,382259 claims
PfizerEliquis, Paxlovid$52$89,79291 claims
Novo NordiskOzempic$102$71,21939 claims
AbbVieLinzess, Creon$77$53,35535 claims
MerckJanuvia$29$30,96027 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,979 internal medicine providers in Maryland.

Other internal medicine in Hagerstown

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →